Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker

Area of Science:

• Oncology
• Biomarker Discovery
• Molecular Imaging

Background:

• Prostate cancer remains a leading cause of cancer death in men.
• Current markers like prostate-specific antigen (PSA) have limitations, necessitating novel diagnostic and therapeutic targets.
• Prostate-specific membrane antigen (PSMA) is a transmembrane protein highly expressed in prostate cancer.

Purpose of the Study:

• To evaluate prostate-specific membrane antigen (PSMA) as a novel biomarker for prostate cancer.
• To explore the diagnostic and therapeutic potential of PSMA and its targeting agents.
• To investigate the expanded expression of PSMA in tumor neovasculature.

Main Methods:

• Review of existing literature on PSMA expression and its clinical applications.
• Analysis of diagnostic and therapeutic trials utilizing anti-PSMA monoclonal antibodies (mAbs).
• Examination of recent findings on PSMA expression in tumor neovasculature.

Main Results:

• Anti-PSMA monoclonal antibody (mAb) 7E11 is used for diagnosing prostate cancer metastasis and recurrence.
• Phase I and II trials show promising therapeutic results using PSMA-targeting agents.
• PSMA is expressed in endothelial cells of tumor-associated neovasculature, broadening its utility.

Conclusions:

• PSMA is a valuable target for both diagnosis and therapy in prostate cancer.
• The discovery of PSMA in tumor neovasculature significantly expands its potential clinical applications.
• Ongoing development of anti-PSMA mAbs promises further advancements in prostate cancer management.